Showing results (911-920 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|January 26, 2026
Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancerPingting Ye, Yixuan Wen, Rui Liu, et al.
NPJ Breast Cancer|January 16, 2026
Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumorsLin Wang, Brian R Sardella, Emily K Aronson, et al.
NPJ Breast Cancer|January 23, 2026
Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United StatesPegah Farrokhi, Leah Park, Weston Schmutz, et al.
NPJ Breast Cancer|January 8, 2026
Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profilesDane Cheasley, Meagan Ruppert, Lisa Devereux, et al.
NPJ Breast Cancer|November 26, 2025
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabGiorgio Bonomi, Gaia Griguolo, Tommaso Giarratano, et al.
NPJ Breast Cancer|November 24, 2025
DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancerElizabeth M Chislock, Tien-Chi Pan, Dhruv Pant, et al.
NPJ Breast Cancer|November 20, 2025
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancerMary S Guirguis, Beatriz E Adrada, Clinton Yam, et al.
NPJ Breast Cancer|December 18, 2025
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitinationJunnai Wang, Yanhua Dong, Weiwei Lun, et al.
NPJ Breast Cancer|February 7, 2026
Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancerJustine Pasanisi, Constance Lamy, Lolita Lecompte, et al.
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Pageof 98